Skip to content

Risk Stratification Using Midregional Proadrenomedullin in the ED

IDEntifying pAtients With Suspicion of Infection in the ED Who Have Low Disease Severity Using Midregional Proadrenomedullin (MR-proADM) - Pivotal Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05108883
Enrollment
463
Registered
2021-11-05
Start date
2021-10-14
Completion date
2023-11-07
Last updated
2025-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients Presenting With Suspicion of Infection to the ED

Brief summary

Emergency departments (ED) are becoming increasingly over-crowded, with patients facing prolonged waiting times. Therefore, a safe and rapid assessment that identifies patients with low severity that could be treated as outpatients is essential for improving the workflow within the ED. The rationale of this IDEAL+ study is to safely decrease the number of hospital admissions through identification of low risk patients with the biomarker MR-proADM. This will has already been tested in the IDEAL - pilot study and results should be confirmed with this IDEAL+ study.

Interventions

DEVICEMR-proADM KRYPTOR

MR-proADM ≤ 0.87 nmol/L together with routine clinical evaluation identifies patients with low disease severity who do not need to be hospitalized

Sponsors

Brahms AG
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Consecutive patients presenting to the ED with suspicion of infection 2. Age ≥18 years 3. Written Informed Consent obtained

Exclusion criteria

1. Patients with SARS-COV-2 infection 2. Recent major trauma or surgery 3. End stage renal failure requiring dialysis 4. Terminal disease and/or very severe medical co-morbidity where death has to be expected in the next 6 months, e.g. due to malignancy, cardiac, renal or hepatic failure 5. Patients whose source of infection always requires hospital admission or never requires hospital admission. 6. Patients who cannot be discharged for other than medical reasons 7. Patient participates in any other interventional clinical trial 8. Patients with active abusive drug use 9. Pregnant or lactating women 10. Patients who are institutionalized by official or judicial order 11. Dependents of the sponsor, the CRO, the study site or the investigator

Design outcomes

Primary

MeasureTime frameDescription
Number of out-patients re-presenting to the ED5 daysNumber of out-patients re-presenting to the ED

Countries

France, Italy, Spain, United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026